ストックスクリーナーアプリを入手
0.3789
3.05%
0.0112
プレマーケット:
.36
-0.0189
-4.99%
前日終値:
$0.3677
開ける：
$0.346
24時間の取引高:
11.73M
Relative Volume:
0.61
時価総額：
$6.44M
収益：
-
当期純損益:
$-12.89M
株価収益率:
-0.1498
EPS:
-2.53
ネットキャッシュフロー:
$-11.95M
1週間 パフォーマンス:
+30.16%
1か月 パフォーマンス:
-41.52%
6か月 パフォーマンス:
-71.72%
1年 パフォーマンス:
-83.16%
1日の値動き範囲:
$0.346
$0.45
1週間の範囲:
$0.268
$0.661
52週間の値動き範囲:
$0.26
$2.6702
Plus Therapeutics Inc Stock (PSTV) Company Profile
PSTV を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PSTV
Plus Therapeutics Inc
|
0.3789 | 4.95M | 0 | -12.89M | -11.95M | -2.53 |
|
ONC
Beone Medicines Ltd Adr
|
251.72 | 25.78B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
446.48 | 114.53B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.3401 | 40.54M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
84.81 | 6.44B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
487.86 | 65.13B | 14.09B | 4.50B | 2.96B | 39.28 |
Plus Therapeutics Inc Stock (PSTV) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-03-17 | 開始されました | D. Boral Capital | Buy |
| 2021-01-25 | 開始されました | Ladenburg Thalmann | Buy |
| 2020-10-16 | 開始されました | Maxim Group | Buy |
Plus Therapeutics Inc (PSTV) 最新ニュース
Plus Therapeutics Reports Q1 2025 Financial Results - TipRanks
Plus Therapeutics (PSTV) Reports Significant Q1 Earnings Miss - GuruFocus
Plus Therapeutics (PSTV) Reports Q1 Loss, Misses Revenue Estimates - MSN
Plus: Q1 Earnings Snapshot - New Haven Register
Plus Therapeutics reports Q1 EPS ($1.19) vs. (75c) last year - TipRanks
Plus Therapeutics (PSTV) Reports Financial Gains from Grant Reve - GuruFocus
Earnings Flash (PSTV) Plus Therapeutics Reports Q1 Loss $-1.19 Per Share, vs. FactSet Est of $-0.25 - marketscreener.com
Plus Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Plus Therapeutics Reports First Quarter Financial Results and Recent Business Highlights | PSTV Stock News - GuruFocus
Plus Therapeutics Reports First Quarter Financial Results and Recent Business Highlights - The Manila Times
PLUS THERAPEUTICS, INC. SEC 10-Q Report - TradingView
Should Plus Therapeutics Inc (NASDAQ: PSTV) Investors Be Concerned? - Stocksregister
DeFi Technologies Provides Monthly Corporate Update: Valour Reports C$1.18 Billion (US$819 Million) AUM, and Record Monthly Net Inflows of C$56 Million (US$38.8 Million) in December 2024 - The Globe and Mail
3 No-Brainer Cloud Computing Stocks to Buy Right Now - The Globe and Mail
Plus Therapeutics recives Nasdaq delinquency notice - MSN
Plus Therapeutics, Inc. Receives Notification of Deficiency from - GuruFocus
Plus Therapeutics (PSTV) Faces Nasdaq Compliance Challenge - GuruFocus
Plus Therapeutics Faces Nasdaq Compliance Notice - TipRanks
Plus Therapeutics, Inc. Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Quarterly Report on Form 10-Q | PSTV Stock News - GuruFocus
Plus Therapeutics, Inc. Receives Notification of Deficiency - GlobeNewswire
Plus Therapeutics Receives Nasdaq Warning: Company Has 60 Days to Submit Compliance Plan - Stock Titan
SBAC Stock Rises 12% Year to Date: Will the Trend Continue? - The Globe and Mail
Plus Therapeutics Receives Nasdaq Delisting Notice - TipRanks
Corpay Stock Jumps 25% in a Year: Here's What You Should Know - The Globe and Mail
Tesla Stock Powers Up for Fourth Straight Week of Gains - The Globe and Mail
Plus Therapeutics Delays Quarterly Report Filing - TipRanks
Plus Therapeutics (PSTV) May Report Negative Earnings: Know the Trend Ahead of Q1 Release - MSN
Plus Therapeutics reports progress in CNS cancer therapy By Investing.com - Investing.com Nigeria
Plus Therapeutics (PSTV) Showcases Promising REYOBIQ Data at Con - GuruFocus
Plus Therapeutics' REYOBIQ™ Shows Clinical Benefit and Safety in - GuruFocus
Plus Therapeutics Presents Promising ReSPECT Trial Data on REYOBIQ for Leptomeningeal Metastases at 2025 Nuclear Medicine and Neurooncology Conference - Nasdaq
Plus Therapeutics reports progress in CNS cancer therapy - Investing.com
Plus Therapeutics’ REYOBIQ™ Shows Clinical Benefit and - GlobeNewswire
Plus Therapeutics’ REYOBIQ™ Shows Clinical Benefit and Safety in the ReSPECT-LM Clinical Trial for Patients with Leptomeningeal Metastases (LM) - TradingView
Plus Therapeutics (PSTV) Showcases Promising REYOBIQ Data at Conference | PSTV Stock News - GuruFocus
Plus Therapeutics (PSTV) Expected to Announce Earnings on Wednesday - Defense World
Leptomeningeal Metastases Pipeline 2025: Key Companies, MOA, - openPR.com
Plus Therapeutics to Participate in the D. Boral Capital Inaugural Global Conference - GlobeNewswire
Plus Therapeutics (NASDAQ:PSTV) Stock Rating Lowered by D Boral Capital - Defense World
Plus Therapeutics (NASDAQ:PSTV) Given Hold Rating at D. Boral Capital - Defense World
Plus Therapeutics (PSTV) Downgraded Amid Planned Reverse Stock S - GuruFocus
Colorectal Cancer Pipeline 2025: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight | Novartis, Pharma Oncology, Purple Biotech Ltd, Plus Therapeutics, Processa - Barchart.com
This Block Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday - Benzinga
Plus Therapeutics (PSTV) Receives Downgrade to Hold by D. Boral Capital | PSTV Stock News - GuruFocus
PSTV Stock Sees Decline of Approximately -22.86% in Last Five Days - knoxdaily.com
Form 8-KCurrent report - ADVFN
Plus Therapeutics Inc (PSTV) can make a big difference with a little luck - Sete News
Investing in Plus Therapeutics Inc (PSTV): What You Must Know - knoxdaily.com
Plus Therapeutics Inc (PSTV) 財務データ
収益
当期純利益
現金流量
EPS
0.87%
0.19%
大文字化:
|
ボリューム (24 時間):